期刊文献+

高效液相色谱法测定大鼠血浆内厄洛替尼的浓度及其药动学研究 被引量:2

HPLC determination of erlotinib in rat plasma and its pharmacokinetics
下载PDF
导出
摘要 目的建立以高效液相色谱法测定大鼠血浆中厄洛替尼浓度的方法,并研究其在大鼠体内的药物动力学。方法色谱柱为Dikma Diamonsil C18,流动相为乙腈-水=60∶40(pH=2.0),流速为1.2 mL.min-1,柱温为35℃;检测波长331nm。结果厄洛替尼血药浓度在80~4 000ng.mL-1与峰面积线性关系良好(r=0.997 7),最低检测限为80ng.mL-1;日内、日间RSD均≤10%,提取回收率在83.77%~85.68%。6只SD大鼠单剂量静脉给予厄洛替尼(10mg.kg-1)后药动学参数分别为:Cmax=(1.203×103±118.2)ng.mL-1;t1/2=(23.24±2.33)h;AUC0-t=(4.713×103±213.6)ng.h.mL-1;AUC0-∞=(5.363×103±323.6)ng.h.mL-1;MRT=(25.91±2.34)h;Vd=(28.44±1.58)L。结论本方法简便、准确、灵敏、专属性强,同样适用于人血浆中厄洛替尼浓度的测定及其药动学研究,对于评价厄洛替尼疗效和安全性有重要意义。 Objective To develop a simple and sensitive HPLC method to determine the content of erlotinib in rat plas ma. Methods The chromatographic separation was carried out on a Dikma Diamonsil Cls column with the mobile phase consisting of acetonitrile-water (60 : 40, v/v, pH=2.0) at 1.2 mL . min -1. The column temperature was 35 ℃. The detection wavelength was 331 nm. Results The calibration was linear at 80--4 000 ng . mL -1 for erlotinib. The inter- and intra-day RSDs were less than 10%.The pharmacokinetic parameters were: Cmax (1 203. 12± 118. 23) ng. mL-1 ; t1/2 (23.24±2.33) h; AUC0-t (4 713.25±213.55) ng . h . mL-1 ; AUC0-∞ (5 363.38±323.62) ng . h .mL-1 ; MRT (25.91±2.34) hi Va (28.44± 1.58) L. Conclusion This method is simple, sensitive and accurate, which can be used in routine clinical practice to monitor erlotinib concentration in the plasma from non-small cell lung cancer patients.
出处 《中南药学》 CAS 2012年第4期248-250,共3页 Central South Pharmacy
关键词 厄洛替尼 高效液相色谱法 药动学 erlotinib HPI.C pharmacokinetics
  • 相关文献

参考文献9

  • 1Carr LL, Finigan JH, Kern JA. Evaluation and treatment of patients with non small cell lung cancer [J]. Med Clin North Am, 2011, 95 (6): 1041-1054.
  • 2Lal R, Enting D, Kristeleit H. Systemic treatment of non- small-cell lung cancer [J]. Eur J Cancer, 2011, 47 (suppl 3) : S375-S377.
  • 3Yim KL, Cunningham D. Targeted drug therapies and cancer [J]. Recent Results Cancer Res, 2011, 185 (1): 159-171.
  • 4G6tze L, Hegele A, Metzelder SK, et al. Development and clinical application of a LC-MS/MS method for simultaneous de- termination of various tyrosine kinase inhibitors in human plas- ma [J]. Clin Chim Aeta, 2012, 413 (1-2): 143- 149.
  • 5Faivre L, Gomo C, Mir O, et al. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma[J]. J Chromatogr B Analyt Technol BiomedLifeSci, 2011, 879 (23).. 2345-2350.
  • 6Lu X, Xiao B, Lo L, et al. Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection [J]. J Pharm Biomed Anal, 2011, 56 (1): 23-29.
  • 7Hou X, Wang S, Hou J, et al. Establishment of A431 cell membrane ehromatography-RPLC method for screening target components from Radix Caulophylli [J]. J Sep Sci, 2011, 34 (5): 508-513.
  • 8Costa DB, Kobayashi S, Yeo WL, et al. Serum concentra- tions of Erlotinib at a dose of 25 mg daily [J]. J Thorac Oncol, 2010, 5 (8):1311-1312.
  • 9Chahbouni A, den Burger JC, Vos RM, et al. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry [J]. Ther Drug Monit, 2009, 31 (6): 683 -687.

同被引文献19

  • 1刘向峰,魏红燕.脉冲给药系统用于哮喘及心血管疾病研究进展[J].食品与药品,2007,9(06A):47-49. 被引量:5
  • 2马艳杰,毛燕欣.盐酸厄洛替尼[J].中国新药杂志,2007,16(11):903-904. 被引量:15
  • 3Bjorn L. The importance of circadian rhythms on drug response in hypertension and coronary heart disease from mice and man [J]. Pharmacol Therapeutics, 2006, 60 ( 8 ) : 629- 651.
  • 4Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavai- lability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats [J]. J Ethnopharmacol, 2003, 84 ( 2-3 ) : 187.
  • 5MOYER J D, BARBACCI E G, IWATA K K, et al.Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase [ J] .Cancer Res, 1997,57(21) :4838-4848.
  • 6GOTZE L, HEGELE A, METZELDER S K,et al.Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma [ J ].Clin Chim Acta, 2012,413(1/2) : 143-149.
  • 7FAIVRE L, GOMO C, MIR O,et al.A simple HPL C-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2011,879 ( 23 ) : 2345-2350.
  • 8LU J F, EPPLER S M, WOLF J, et al. Clinical pharma- cokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer [ J ]. Clin Pharmacol Ther, 2006,374 (80) : 136- 145.
  • 9COSTA D B, KOBAYASHI S,YEO W L, et al.Serum concentrations of Erlotinib at a dose of 25 mg daily [ J ]. J Thorac Oneo1,2010,5(8) : 1311-1312.
  • 10CHAHBOUNI A, DEN BURGER J C, VOS R M, et al. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid ehromatography tandem mass speetrometry [ J].Ther Drug Monit, 2009,31 ( 6 ) : 683- 687.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部